Abdominal wall endometriosis (AWE) is an underappreciated condition that carries a disproportionate burden for the women it affects. Defined by the ectopic implantation of endometrial-like tissue within the abdominal wall superficial to the peritoneum, AWE most commonly arises on cesarean section scars — a context increasingly relevant as cesarean rates climb globally. Its hallmark is cyclical, often severe pain localized to a palpable nodule, with median visual analog scale (VAS) scores of 8/10 recorded consistently across published cohorts. Yet for most of the past several decades, therapeutic options were limited to hormonal suppression or wide surgical excision, each carrying meaningful drawbacks in terms of morbidity, aesthetics, and recurrence.
Over the past decade, percutaneous image-guided cryoablation has emerged as a credible alternative — and the evidence base has now reached a level of maturity that warrants a serious conversation about where cryoablation fits in the standard of care.
A decade of converging evidence
The story begins in 2014 with the first published experience of percutaneous cryoablation for symptomatic abdominal scar endometrioma, establishing technical feasibility and an early signal of efficacy. Since then, multiple cohorts from independent institutions have reported consistent findings. A 2024 systematic review synthesizing eight studies and over a decade of published literature confirmed that pain scores fall from a median of 8/10 to 1/10 at last follow-up (p < 0.0001), that complete local pain response rates range from 80% to 100%, and that no patient across any included study reported a post-procedure pain score higher than their baseline. Major complications occurred in fewer than 2% of cases.
The long-term data are equally reassuring. A cohort of 40 consecutive patients followed for a median of 40.5 months demonstrated pain-free survival rates of 89.2% at 36 months and 76.8% at 60 months, with complete restoration of treated areas confirmed on MRI in patients evaluated at five years — no residual scar, no enhancement. A mid-term single-institution study including 42 patients with extraperitoneal endometriosis reported pain-free survival of 93.8% at six months and 82.7% at twelve months, with an efficacy rate to avoid secondary surgery of 92.8% per patient.
Why cryoablation?
The mechanistic advantages of cryoablation over heat-based alternatives are not incidental to these outcomes — they are central to them. Cryoablation induces cell death through ice crystal formation, cellular dehydration, apoptosis, and vascular disruption while preserving the collagen matrix. This matters enormously in the abdominal wall, where cosmetic outcomes and structural integrity are clinical priorities. Heat-based techniques — radiofrequency ablation, microwave ablation, and high-intensity focused ultrasound — carry inherent risks of retractile scarring, skin burns, and, crucially, the absence of real-time visualization of the ablation zone. The ice ball is visible under ultrasound and CT in real time, enabling the operator to confirm coverage of the target while protecting skin, bowel, and adjacent structures through adjunctive techniques including hydrodissection and carbodissection.
The most comprehensive comparative review to date, encompassing 2,674 patients across 51 studies, confirmed that while surgery achieves the highest local tumor control rates, it does so at the cost of mesh implantation in approximately 16% of patients, major complications in 25 patients, and aesthetic sequelae in up to 69% in comparative series. Cryoablation demonstrated the lowest adverse event rate of any active modality, with major complications in a single patient across 103 treated cases.
Where the field goes next
The session at CIRSE 2026 will be an opportunity to look squarely at what the evidence does and does not yet tell us. The retrospective, single-institution design dominates the literature; selection bias through multidisciplinary case-by-case discussion is present in virtually every published cohort; and the follow-up for cryoablation, while now extending to five years, remains shorter in aggregate than the surgical literature. The CRYOENDOMET trial (NCT03627676) represented a step toward prospective evidence, but the field needs well-powered, multicenter, comparative trials or registries with standardized outcome definitions, long-term imaging follow-up, and patient-reported cosmetic outcomes.
Reimbursement is the other frontier. Cryoablation’s clinical utility is now well enough established that the absence of tailored reimbursement pathways in most health systems constitutes a barrier to equitable access — one that advocacy from the interventional radiology community must address.
Conclusion
AWE cryoablation has traveled from initial case reports to systematic reviews and five-year outcome data within a single decade. The technique is safe, reproducible, and effective. For women of reproductive age carrying the burden of a painful abdominal wall nodule — often already navigating multiple prior surgeries and the impact of endometriosis on their quality of life — cryoablation offers a genuinely attractive option: outpatient, minimally scarring, and repeatable. At CIRSE 2026, we will examine where the evidence is solid, where uncertainty remains, and what the community needs to do to bring this technique fully into evidence-based guidelines.
